Document is current
Any future updates will be listed below
-
Authors
Nieto-Jiménez, Cristina
Garcia-Lorenzo, Esther
Diaz-Tejeiro, Cristina
Paniagua-Herranz, Lucía
Sanvicente, Adrián
Doger, Bernard
Moreno, Irene
Pedregal, Manuel
Bartolomé, Jorge
Manzano, Arancha
Munkácsy, Gyöngyi
Győrffy, Balázs
Pérez-Segura, Pedro
Calvo, Emiliano
Moreno, Victor
Ocana, Alberto
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI19/00808)
CRIS Cancer Foundation (AOF.C01 CRIS)
- License Information
-
More Information
Article History
Received: 24 April 2024
Accepted: 13 May 2025
First Online: 22 May 2025
Declarations
:
: A.O. is currently a consultant for NMS outside the current work and consultant services for Servier, Worldwide International Trials and CancerAppy. Former employee of Symphogen. No conflict of interest to declare in relation to this manuscript. V.M. reports personal fees from Bristol-Myers Squibb, Bayer, Janssen, and Pieris outside the submitted work. E.C. reports grants and personal fees from Astellas, Novartis, Nanobiotix, Pfizer, Janssen-Cilag, PsiOxus Therapeutics, Merck, BristolMyers Squibb, Seattle Genetics, Boehringer Ingelheim, AstraZeneca, Roche/Genentech, Servier, Celgene, AbbVie, Amcure, Alkermes, PharmaMar, and BeiGene, outside the submitted work. P.P. reports grant/research support from Bristol-Myers Squibb, AstraZeneca, and MSD, outside the submitted work. The other authors declare that they have no competing interests.
